Lumenis Be. Ltd. is partnering with Bosley to introduce FoLix, the first and only U.S. Food and Drug Administration-cleared fractional laser for hair loss treatment.
Bosley is first national hair restoration medical practice in the U.S to offer FoLix. The company initially offered FoLix at its Beverly Hills, CA location in Sept. 2024 and plans to roll out the service at its other locations across the country. FoLix is a non-ablative fractional laser device indicated for improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss.
“Staying at the forefront of innovations and excellence, we are always looking for the latest and most effective advancements to support our customers in their hair restoration journey,” says Rob Spurrell, CEO and President of Bosley, in a news release. “FoLix is a strong and perfect fit for our expanding range of solutions, as it offers a non-surgical, in-office approach with minimal discomfort, showing promising results in several monthly sessions.”
“At Bosley, we understand the profound impact that hair loss can have on our patients’ lives. We have been helping patients with hair loss, surgically and non-surgically, with emerging technology for 50 years, and we are excited to introduce the Lumenis FoLix treatment, an innovative treatment designed to help our patients restore their hair and confidence,” adds Ken Washenik, MD PhD, Chief Medical Officer at Bosley.
